This document and its members confirm that the information is true, accurate, complete, and free from false records, misleading statements, or major omissions.
On March 10, 2026, the company, Pura Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), held its 2026 annual general meeting. The Board Compensation and Assessment Committee approved the initial grant of the 2026 stock option incentive plan (hereinafter referred to as "the Plan") and related proposals.
According to the "Management Measures for Stock Option Incentive Plans" (hereinafter referred to as "Management Measures") and the relevant provisions of the Company Law, the Company will publicly disclose the following regarding the initial grant of stock options under the Plan:
1. Public Disclosure Information
- Content: This incentive plan involves the initial grant of stock options to designated recipients.
- Time: From March 31, 2026, to March 20, 2026, totaling 10 days.
- Method: The Company will issue an announcement.
- Feedback: During the grant period, employees may provide feedback in writing to the Board Compensation and Assessment Committee regarding the Plan.
- Conclusion: The public disclosure period will allow the Board Compensation and Assessment Committee to collect opinions from relevant stakeholders regarding the designated recipients of the stock options.
2. Review Opinion of the Board Compensation and Assessment Committee
The Board Compensation and Assessment Committee, based on the "Management Measures" for the incentive plan, has reviewed the designated recipients of the stock options under the 2026 stock option incentive plan (hereinafter referred to as "the designated recipients") and believes the following: